Tvardi Therapeutics, Inc. (TVRD) intrinsic value & 10-year financials
Tvardi Therapeutics, Inc. (TVRD) has a Graham intrinsic value of $5.98 per share. At $1.01 on Oct 17, 2026, the stock trades 83% below that value.
- Graham intrinsic value
- $5.98
- Share price (Oct 17, 2026)
- $1.01
- Price vs Graham value
- 83% below
- Market cap
- $7.9M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 73.7%
- ROIC (10-yr avg)
- -110.9%
- Free cash flow (FY2025)
- —
TVRD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$18.2M | -$3.26 | — | — | 127.4% |
| FY2024 | $7.1M | -$70.9M | -$15.53 | -$62.0M | -818.0% | 375.8% |
| FY2023 | $21.0M | -$118.5M | -$2.19 | -$94.5M | -579.4% | -1065.9% |
| FY2022 | $41.9M | -$85.5M | -$1.59 | -$78.8M | -209.1% | — |
| FY2021 | $23.0M | -$88.4M | -$1.74 | -$60.1M | -386.8% | -40.8% |
| FY2020 | $135.1M | $8.4M | $0.18 | -$5.8M | 4.0% | 2.7% |
| FY2019 | $19.9M | -$106.4M | -$2.49 | -$109.2M | -561.6% | -64.5% |
| FY2018 | $13.5M | -$74.0M | -$2.06 | -$22.4M | -574.5% | — |
| FY2017 | $911.0K | -$58.1M | — | -$54.9M | -6529.6% | — |
| FY2016 | $86.0K | -$57.3M | — | -$48.1M | -67907.0% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Tvardi Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Tvardi Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just 3.0% ROIC.
Over the decade, Tvardi Therapeutics, Inc. shows that management has aggressively returned capital to shareholders by retiring 71.5% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Tvardi Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $5.98 per share.